News and Events

October 20, 2022

Strike Pharma and FyoniBio sign Master Service Agreement

Agreement covers Cell Line Development for a novel bi-specific therapeutic mAb

August 30, 2022

Strike Pharma’s Chief Scientific Officer receives BiotechBuilders Award 2022

Dr. Sara Mangsbo acknowledged for entrepreneurship and her contribution to Swedish life science industry

June 20, 2022

Strike Pharma strengthens Board of Directors

Niclas Stiernholm elected as Chairman of the Board

June 6, 2022

Strike Pharma begins expansion of management team

Appoints Lindvi Gudmunsdotter as Director, Non-Clinical Development

May 2, 2022

Strike Pharma, Uppsala University and KTH Royal Institute of Technology present at CIMT 2022

CD40 agonistic, bispecific antibody candidates developed using ADAC technology ensure T-cell activation

April 8, 2022

Strike Pharma and Uppsala University present at AACR 2022

New data demonstrates proof of concept for ADAC technology platform

February 22, 2022

Strike Pharma completes 45 MSEK financing round

Efforts now focus on bringing first candidate to clinical trials and further development of ADAC technology platform

June 18, 2021

Strike raises SEK 10M (>1M $)

Swedish immuno-oncology newcomer STRIKE Pharma raises SEK 10 million for development of individualized solid tumour therapy.

April 28, 2021

Mårten Winge new CEO

STRIKE Pharma appoints industry veteran Mårten Winge as new CEO